Zydus Cadila has received the tentative approval from the USFDA to market Linagliptin and Metformin Hydrochloride Tablets(US RLD - Jentadueto® Tablets),2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. It is used along with diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes mellitus.
The group now has 221 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.375 as compared to the previous close of Rs. 384.25. The total number of shares traded during the day was 77491 in over 1218 trades.
The stock hit an intraday high of Rs. 382.15 and intraday low of 371.25. The net turnover during the day was Rs. 29263408.